Antitumor Effect of Thymosin α1/Interleukin-2 or Thymosin α1/Interferon α,β Following Cyclophosphamide in Mice Injected with Highly Metastatic Friend Erythroleukemia Cells

Journal of Immunotherapy

Volumn 13, Issue 1, 1993, Pages 7-17

  Garaci, Enrico ^a   Pica, Francesca ^a,b   Mastino, Antonio ^a   Palamara, Anna Teresa ^a   Belardelli, Filippo ^c   Favalli, Cartesio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CNR   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cyclophosphamide; Friend erythroleukemia cell tumor; Interferon; Interleukin 2; Thymosin 1

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYCLOPHOSPHAMIDE; INTERLEUKIN 2; THYMOSIN ALPHA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CYTOTOXICITY; ERYTHROLEUKEMIA CELL; IMMUNOREACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOID CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL TIME; TUMOR REGRESSION;

ANIMAL; ANTIGENS, CD4; ANTIGENS, CD8; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FRIEND MURINE LEUKEMIA VIRUS; G(M1) GANGLIOSIDE; INTERFERON-ALPHA; INTERFERON-BETA; INTERLEUKIN-2; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LEUKEMIA, EXPERIMENTAL; MALE; MICE; MICE, INBRED DBA; SUPPORT, NON-U.S. GOV'T; THYMOSIN; TUMOR VIRUS INFECTIONS;

EID: 0027472234     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199301000-00002     Document Type: Article

References (41)

1. Garaci E, Mastino A, Jezzi T, Favalli C. Thymic hormones and cytokines:a synergystic combination with high therapeutic potentialities. In: Dammacco F., ed. Recent advances in autoimmunity and tumor immunology. Milano: Edi. Ermes, 1988:211-20.
2. Garaci E, Mastino A, Favalli C. Enhanced immune response and antitumor immunity with combinations of biological response modifiers. Bull NY Acad Med 1989;65:111-19.
3. Brunda MJ, Bellantoni D, Sulich V. In vivo anti-tumor activity of combinations of interferon a and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 1987;40:365-71.
4. Ciolli V, Gabriele L, Sestili P, et al. Host antitumor mechanism in the combined IL-l/IL-2 therapy in mice injected with highly metastatic Friend leukemia cells. Effects on established metastates. J Exp Med 1991;173:313-22.
5. Belardelli F, Ciolli V, Testa U, et al. Antitumor effects of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors. Int J Cancer 1989;44:1108-16.
6. Belardelli F, Gabriele L, Proietti E, et al. Sinergistic antitumor effects of combined IL-1/IFN-α/ß therapy in mice injected with metastatic Friend erythroleukemia cells. Int J Cancer 1991;49:274-8.
7. Iigo M, Sakurai M, Tamura T, Saijo N, Hoshi A. In vivo antitumor activity of multiple injections of recombinant interleukin-2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. Cancer Res 1988;48:260-4.
8. McIntosh JK, Mule JJ, Krosnick JA, Rosenberg SA. Combination cytokine immunotherapy with tumor necrosis factor a, interleukin 2, and α-interferon and its synergistic antitumor effects in mice. Cancer Res 1989;49:1408-14.
9. Old LJ. Polypeptide mediator network. Nature 1987;326:330-1.
10. Forni G, Giovarelli M, Santoni A, Modesti A, Forni M. Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity. J Immunol 1987;138:4033-41.
11. Goldstein A, Low TLK, Adoo M, et al. Thymosin alpha 1:isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA 1977;74:725-9.
12. Favalli C, Jezzi T, Mastino A, Rinaldi-Garaci E, Riccardi C, Garaci E. Modulation of natural killer activity by thymosin alpha 1 and interferon. Cancer Immunol Immunother 1985;20:189-92.
13. Favalli C, Mastino A, Jezzi T, Grelli S, Goldstein A. Synergistic effect of thymosin alpha 1 and alpha-beta interferon on NK activity in tumor bearing mice. Int J Immunopharmacol 1989:5:443-9.
14. Mastino A, Favalli C, Grelli S, Innocenti F, Garaci E. Thymosin al potentiates interleukin 2 induced cytotoxic activity in mice. Cell Immunol 1991,133:196-205.
15. Garaci E, Mastino A, Pica F, Favalli C. Combination treatment using thymosin α1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice. Cancer Immunol Immunother 1990;32:154-60.
16. Mastino A, Favalli C, Grelli S, et al. Combination therapy with thymosin α1 potentiates the antitumor activity of interleukin 2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int J Cancer 1992;50:493-9.
17. Belardelli F, Gresser I, Maury C, Duvillard P, Prade M, Maunoury MT. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend Leukemia cells. III. Inhibition of growth and necrosis of tumor implanted subcutaneously. Int J Cancer 1983;31:649-53.
18. Gresser I, Maury C, Woodrow D, et al. Interferon treatment markedly inhibits the development of tumor metastases in the liver and spleen and increases survival time of mice after intravenous inoculation of Friend erythroleukemia cells. Int J Cancer 1988;41:135-42.
19. Gresser I, Maury C, Carnaud C, De Maeyer E, Maunoury MT, Belardelli F. Antitumor effects of Interferon in mice injected with interferon-sensitive and interferon-resistant Friend erythroleukemia cells. VIII. Role of the immune system in the inhibition of visceral metastases. Int J Cancer 1990;46:468-74.
20. Gresser I, Carnaud C, Maury C, et al. Host humoral and cellular mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon α,ß treatment in mice. J Exp Med 1991;173:1193-203.
21. Belardelli F, Ferrantini M, Maury C, Santurbano L, Gresser I. On the biologic and biochemical differences between in vitro and in vivo passaged Friend erythroleukemia cells. Tu-morigenicity and capacity to metastasize. Int J Cancer 1984;34:389-95.
22. Affabris E, Jemma C, Rossi GB. Isolation of interferon-resistant variants of Friend erythroleukemia cells:effect of interferon and ouabain. Virology 1982;120:441-52.
23. Amici C, Ferrantini M, Benedetto A, Belardelli F, Gresser I. On the biologic and biochemical differences between in vitro and in vivo passaged Friend erythroleukemia cells. Tumor-igenicity and capacity to metastasize. II. Changes in cell surface glycoproteins associated with a highly malignant phenotype. Int J Cancer 1984;34:397-402.
24. Habu S, Fukui H, Shimamura K, et al. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol 1981;127:35-8.
25. Dialynas DP, Quan ZS, Wall KA, et al. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK 1.5:similarity of L3T4 to the human leu-3/T4 molecule. J Immunol 1983;131:2445-51.
26. Wilde DB, Marrack P, Kappler J, Dialynas DP, Fitch FW. Evidence implicating L3T4 in class II MHC antigen reactivity:monoclonal antibody GK 1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lympho-kines, and binding by cloned murine helper T lymphocyte lines. J Immunol 1983;131:2178-83.
27. Ledbetter JA, Herzenberg LA. Xenogenic monoclonal anti- bodies to mouse lymphoid differentiation antigens. Immunol Rev 1979;47:63-90.
28. Hanna N. In vivo activities of NK cells against primary and metastatic tumors in experimental animals. In: Lotzova E, Herberman RB, eds. Immunobiology of natural killer cells. Boca Raton: CRC Press, 1986:1-10.
29. Herberman RB. Natural killer (NK) cells:characteristics and possible role in resistance against tumor growth. In: Reif AE, Mitchell MS, eds. Immunity to cancer. Orlando: Academic Press, 1985:217-9.
30. Wise JA, Mokyr MB, Dray S. Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune response of spleen cells from mice bearing large MOPC-315 plasmocytomas. Cancer Immunol Immunother 1988;27:191-7.
31. North RJ. Cyclophosphamide-facilitated adoptive immuno-therapy of established tumors depends on the elimination of tumor induced suppressor cells. J Exp Med 1982;155:1063-74.
32. Punturieri A, Santoni A, Ming WJ, Nobili N, Mantovani A, Bottazzi B. In vitro migration of rat large granular lymphocytes. Cell Immunol 1989;123:257-67.
33. Weisenthal LM, Dill PL, Pearson FC. Effect of prior cancer chemotherapy on human tumor-specific cytotoxicity in vitro in response to immunopotentiating biologic response modifiers. J Natl Cancer Inst 1991;83:37-42.
34. Papa MZ, Yang JC, Vetto JT, Shiloni E, Eisenthal A, Rosenberg SA. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors. Cancer Res 1988;48:122-9.
35. Hosokawa M, Sawamura Y, Morikage T, et al. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide. Cancer Immunol Immunother 1988;26:250-6.
36. Sztein MB, Serrate SA. Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. Int J Immunopharmacol 1989;11:789-800.
37. Serrate SA, Schulof RS, Leondaridis L, Goldstein AL, Sztein M. Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin 2-receptor expression by thymic hormones. J Immunol 1987;139:2338-43.
38. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwartz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high doses of recombinant interleukin 2. J Exp Med 1985;161:1169-88.
39. Rosenberg SA. Immunotherapy of cancer using interleukin 2:current status and future prospects. Immunol Today 1988;9:58-62.
40. Zimmerman RJ, Stacey G, Chan A, Landre P, Winkelhake JL. Sequence dependence of administration of human re-combinant tumor necrosis factor and interleukin-2 in murine tumor therapy. J Natl Cancer Inst 1989;81:227-31.
41. Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 1986;137:1735-42.